FDA approves Foundayo (orforglipron), the first once-daily GLP-1 pill for obesity without food or water restrictions

The Food and Drug Administration approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 tablet, on April 1, 2026, for adults with obesity or adults with overweight plus at least one weight-related medical condition, used with a reduced-calorie diet and increased physical activity ^[1][3]. It is the second oral GLP-1 approved for weight management, following Novo Nordisk's Wegovy pill in December 2025 ^[4].

Unlike oral semaglutide, Foundayo is a small-molecule (non-peptide) drug that can be taken any time of day, with or without food, and with no water or 30-minute waiting rule ^[1][3]. The Wegovy pill must be taken in the morning at least 30 minutes before any food or drink other than water ^[4].

What it costs

Lilly published a tiered cash price. The regular self-pay price for a 30-day supply is $149 for the 0.8 mg dose, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg ^[2]. Through December 31, 2026, the 2.5 mg dose is temporarily cut to $149 and the 5.5 mg dose to $199 ^[2]. Lilly also offers a $299 "purchase offer" price on the two highest doses, but keeping it requires refilling within 45 days of the previous shipment's delivery date ^[2].

That pricing is a retreat from what Lilly signaled earlier. The company had said it planned cash prices of $149 to $399 a month; Novo then launched its Wegovy pill at up to $299, and Lilly matched that ceiling for patients who keep renewing ^[4].

People with commercial insurance that covers Foundayo may pay as little as $25 per month with a savings card, but the card caps savings at $100 per 30-day fill and $1,000 per calendar year, allows up to 10 fills a year, excludes anyone in Medicare, Medicaid, TRICARE or VA coverage, and expires December 31, 2026 ^[1][2]. People with commercial insurance that does not cover the drug pay $149 for 0.8 mg or 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg or 17.2 mg ^[2]. Lilly says eligible Medicare Part D patients may be able to get Foundayo for $50 per month through a "Medicare GLP-1 Bridge" program beginning as soon as July 1, 2026, subject to clinical criteria and not a guarantee of coverage ^[1][2].

Dosing and results

Foundayo comes as 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg tablets ^[3]. Treatment starts at 0.8 mg once daily and moves up one step at a time after at least 30 days at each level, to a maximum of 17.2 mg ^[3]. In Phase 3 trials, doses went up to 36 mg in capsule form; Lilly says the approved tablet doses are equivalent ^[4].

In the 72-week ATTAIN-1 trial of 3,127 adults, people on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4%, versus 2.2 pounds (0.9%) on placebo ^[1][3]. Counting everyone regardless of whether they finished, the average loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) ^[1]. STAT reported the Wegovy pill produced 13.6% weight loss in a 64-week trial, compared with 11.2% for orforglipron over 72 weeks ^[4].

Foundayo carries a boxed warning for thyroid C-cell tumors, plus warnings for pancreatitis, severe gastrointestinal reactions, kidney injury from dehydration, low blood sugar, gallbladder disease and aspiration during anesthesia ^[1][3]. The most common side effects are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache and hair loss ^[3]. Lilly also notes that oral birth control pills may not work as well on Foundayo ^[1].

Why it matters for patients

A pill that does not need refrigeration, needles or fasting windows removes several practical barriers, but the posted cash prices climb as the dose climbs — from $149 at the starting dose to $349 at the top dose — so the maintenance dose, not the starting dose, determines long-run cost ^[2]. The $25 commercial card's $1,000 annual cap means it can run out before a year of fills, and several discounts have stated end dates ^[2]. The approval also came through the FDA's commissioner's national priority voucher program, which STAT reports has drawn internal criticism as a channel for political interference ^[4][10].

What happens next

Lilly said prescriptions were accepted immediately, with LillyDirect shipping beginning April 6, 2026, followed by retail pharmacies and telehealth ^[1]. The Medicare $50 program is slated to begin as soon as July 1, 2026 ^[1], and the savings card and temporary price cuts are set to expire December 31, 2026 ^[2]. What insurers will cover long-term is not yet known.